array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(80) "Nasal Polyposis Drugs Market Research Report 2023-2087 – Bosnian National Team" ["snippet_en"]=> string(262) "According to a recent Factor survey, the global nasal polyposis drug is poised to capture significant market opportunities from a variety of end-use industries. This study of the global Nasal Polyposis Drug market provides a comprehensive analysis of the various" ["url"]=> string(100) "https://bnm.ba/news/marktforschungsbericht-fuer-medikamente-gegen-nasenpolyposis-2023-2087-2/503670/" ["image_url"]=> NULL ["source"]=> string(6) "bnm.ba" ["publication_date"]=> string(10) "2024-11-09" ["categories"]=> array(3) { [0]=> string(19) "New Revenue Streams" [1]=> string(15) "Market Movement" [2]=> string(17) "Academic Research" } } [1]=> array(7) { ["title_en"]=> string(114) "Evercore sees Regeneron share price decline as overreaction, bullish on Dupixent as growth engine By Investing.com" ["snippet_en"]=> string(288) "Evercore ISI revised its outlook on Regeneron Pharmaceuticals (NASDAQ: REGN ) on Thursday, lowering its target price on the stock to $1,175.00 from $1,250.00, but maintaining an "Outperform" rating. This adjustment is in response to the expectation that rival drugs may be launched early." ["url"]=> string(63) "https://cn.investing.com/news/company-news/article-93CH-2528069" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-10-26" ["categories"]=> array(4) { [0]=> string(15) "Market Movement" [1]=> string(12) "Stock Market" [2]=> string(14) "Product Launch" [3]=> string(18) "General Investment" } } [2]=> array(7) { ["title_en"]=> string(64) "Regeneron share price decline despite solid financial figures ()" ["snippet_en"]=> string(83) "Regeneron shares: price decline despite solid financial figures () | aktiencheck.de" ["url"]=> string(109) "https://www.aktiencheck.de/news/Artikel-Regeneron_Aktie_Kursrueckgang_trotz_solider_Finanzkennzahlen-17711082" ["image_url"]=> string(78) "https://images.businessradar.com/articles/8da29d23-3138-4a84-8e44-8fb956747d63" ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-10-25" ["categories"]=> array(4) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(12) "Stock Market" [2]=> string(18) "Financial Distress" [3]=> string(15) "Market Movement" } } [3]=> array(7) { ["title_en"]=> string(106) "What the Options Market Tells Us About Regeneron Pharmaceuticals - Regeneron Pharmaceuticals (NASDAQ:REGN)" ["snippet_en"]=> string(104) "Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals." ["url"]=> string(121) "https://www.benzinga.com/insights/options/24/10/41278911/what-the-options-market-tells-us-about-regeneron-pharmaceuticals" ["image_url"]=> string(78) "https://images.businessradar.com/articles/faeae905-8c58-4525-ae19-819936785e34" ["source"]=> string(12) "benzinga.com" ["publication_date"]=> string(10) "2024-10-12" ["categories"]=> array(1) { [0]=> string(15) "Market Movement" } } [4]=> array(7) { ["title_en"]=> string(66) "Regeneron share: price decline despite stable financial figures ()" ["snippet_en"]=> string(83) "Regeneron share: price decline despite stable financial figures () | aktiencheck.de" ["url"]=> string(110) "https://www.aktiencheck.de/news/Artikel-Regeneron_Aktie_Kursrueckgang_trotz_stabiler_Finanzkennzahlen-17638336" ["image_url"]=> NULL ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-10-10" ["categories"]=> array(4) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(12) "Stock Market" [2]=> string(18) "Financial Distress" [3]=> string(15) "Market Movement" } } [5]=> array(7) { ["title_en"]=> string(32) "Ophthalmology Market Size, Share" ["snippet_en"]=> string(140) "Ophthalmology Market Size is expected to reach USD 26 Billion by 2033, from USD 8.3 Billion in 2023, growing at a CAGR of 12.1% (2024-2033)." ["url"]=> string(46) "https://market.us/report/ophthalmology-market/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2c53c098-49cd-4ba0-8c36-ccb75cf90861" ["source"]=> string(9) "market.us" ["publication_date"]=> string(10) "2024-10-09" ["categories"]=> array(1) { [0]=> string(15) "Market Movement" } } [6]=> array(7) { ["title_en"]=> string(142) "Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?" ["snippet_en"]=> string(119) "With its stock down 12% over the past month, it is easy to disregard Regeneron Pharmaceuticals (NASDAQ:REGN). But if..." ["url"]=> string(161) "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/is-weakness-in-regeneron-pharmaceuticals-inc-nasdaqregn-stoc-1" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3fb32a90-795e-4f35-a176-58e0c7544df3" ["source"]=> string(13) "simplywall.st" ["publication_date"]=> string(10) "2024-09-30" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(24) "Stock Research & Ratings" [2]=> string(15) "Market Movement" } } [7]=> array(7) { ["title_en"]=> string(63) "Exploring Regeneron's Future: Innovations and Market Strategies" ["snippet_en"]=> string(147) "Discover the innovative strategies and market challenges faced by Regeneron Pharmaceuticals as it seeks to enhance growth and navigate competition." ["url"]=> string(98) "https://investorshangout.com/exploring-regenerons-future-innovations-and-market-strategies-46733-/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5e6fb2c2-1996-4025-8d52-9513e6fe7118" ["source"]=> string(20) "investorshangout.com" ["publication_date"]=> string(10) "2024-09-30" ["categories"]=> array(4) { [0]=> string(11) "Competition" [1]=> string(5) "R & D" [2]=> string(21) "Competitive Behaviour" [3]=> string(15) "Market Movement" } } [8]=> array(7) { ["title_en"]=> string(63) "Regeneron Pharmaceuticals Set for Growth with Dupixent Approval" ["snippet_en"]=> string(162) "Regeneron Pharmaceuticals is poised for future growth after receiving Dupixent's approval for COPD treatment, reflecting investor confidence and market potential." ["url"]=> string(100) "https://investorshangout.com/regeneron-pharmaceuticals-set-for-growth-with-dupixent-approval-45155-/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d958b088-b490-4840-bcd7-ce42c2c9679c" ["source"]=> string(20) "investorshangout.com" ["publication_date"]=> string(10) "2024-09-28" ["categories"]=> array(2) { [0]=> string(18) "Expansion & Growth" [1]=> string(15) "Market Movement" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(62) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(31) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc